Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006

American Heart Journal

Volumn 157, Issue 1, 2009, Pages

  Fonarow, Gregg C ^a   French, William J ^b   Frederick, Paul D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c ICON Lifecycle Sciences Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PRAVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 57149084663     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.09.001     Document Type: Article

References (17)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
3. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
4. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
5. Pearson T.A., Laurora I., Chu H., et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
6. Fonarow G.C., French W.J., Parsons L.S., et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 103 (2001) 38-44
7. Rogers W.J., Bowlby L.J., Chandra N.C., et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 90 (1994) 2103-2114
8. Every N.R., Frederick P.D., Robinson M., et al. A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project. J Am Coll Cardiol 33 (1999) 1886-1894
9. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Circulation 106 (2002) 1893-1900
10. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 110 (2004) 588-636
11. Zhang J., and Yu K. What's the relative risk? A method of correcting the odds ratios in cohort studies of common outcomes. JAMA 280 (1998) 1690-1691
12. Neter J., Wasserman W., and Kutner M.H. Applied linear statistical models: regression, analysis of variance, and experimental design (1990), Irwin Inc, Homewood, IL
13. Fox K.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297 (2007) 1892-1900
14. Austin P.C., and Mamdani M.M. Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation 112 (2005) 1296-1300
15. Mehta R.H., Montoye C.K., Gallogly M., et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA 287 (2002) 1269-1276
16. LaBresh K.A., Ellrodt A.G., Gliklich R., et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 164 (2004) 203-209
17. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372